89R25425 MCF-D     By: Bucy, et al. H.B. No. 4014     Substitute the following for H.B. No. 4014:     By:  VanDeaver C.S.H.B. No. 4014       A BILL TO BE ENTITLED   AN ACT   relating to a study on the use of psychedelic therapies in the   treatment of certain conditions.          BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:          SECTION 1.  (a) In this Act:                (1)  "Commission" means the Health and Human Services   Commission.                (2)  "Psychedelic therapies" means the use of   3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine   to treat mental health or other medical conditions.          (b)  The commission shall conduct a study on the use of   psychedelic therapies for treatment of post-traumatic stress   disorder, depression, and other co-occurring conditions.          (c)  In conducting the study, the commission shall:                (1)  review clinical trials on the efficacy of using   psychedelic therapies in the treatment of post-traumatic stress   disorder, depression, and other co-occurring conditions;                (2)  review current literature regarding the use of   psychedelic therapies in the treatment of post-traumatic stress   disorder, depression, and other co-occurring conditions;                (3)  review actions of the United States Food and Drug   Administration regarding psychedelic therapies for treatment of   post-traumatic stress disorder, depression, and other co-occurring   conditions;                (4)  evaluate treatment guidelines for use of   psychedelic therapies to treat post-traumatic stress disorder,   depression, and other co-occurring conditions and recommend   guidelines and best practices for providers; and                (5)  evaluate patient access to current treatment for   post-traumatic stress disorder, depression, and other co-occurring   conditions and recommend legislative or other actions necessary to   ensure patient access to psychedelic therapies following approval   by the United States Food and Drug Administration, including   considerations of provider availability, affordability,   accessibility, training and licensure, and other regulatory   requirements.          (d)  In addition to any money appropriated by the   legislature, the commission may solicit and accept federal funds   and gifts, grants, or donations from any source to administer and   finance the study conducted under this section.          (e)  Not later than December 1, 2026, the commission shall   submit to the governor, the lieutenant governor, the speaker of the   house of representatives, and the chair of the standing committee   of each house of the legislature with primary jurisdiction over the   commission a written report that includes:                (1)  the results of the study conducted under this   section; and                (2)  any recommendations for legislative or other   action necessary to ensure patient access to psychedelic therapies   for treatment of post-traumatic stress disorder, depression, and   other co-occurring conditions after those therapies are approved by   the United States Food and Drug Administration.          (f)  This Act expires September 1, 2027.          SECTION 2.  The Health and Human Services Commission is   required to implement a provision of this Act only if the   legislature appropriates money specifically for that purpose.  If   the legislature does not appropriate money specifically for that   purpose, the commission may, but is not required to, implement a   provision of this Act using other money available for that purpose.          SECTION 3.  This Act takes effect September 1, 2025.